Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
39 participants
INTERVENTIONAL
2017-02-14
2017-07-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarker Feedback for Smoking Cessation
NCT02206971
Clinical Response to Biomarker Documentation of Child Secondhand Smoke Exposure
NCT01145729
p16 Methylation for Smoking Cessation
NCT01038492
Project DEDUCE: Digital Envirotyping to Develop Understanding of Cigarette Smoking and the Environment
NCT07089901
Project 1, Study 2: The Combined Impact of Nicotine Replacement and Spectrum Cigarettes
NCT02301325
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. education about harms of smoking (control group);
2. same education plus information on DNA damage and biomarker feedback (biomarker arm) without visual of damage; or
3. same as arm 2 except accompanied with visuals of participants' normal and DNA damage cells. Participants in the this arm will be informed of their proportion of leucocytes showing DNA damage with pictures of their normal and damaged cells.
The goal of the analyses is to obtain effect size estimates (direction, confidence intervals) to inform if results align with hypotheses and obtain insights about reactions about the feedback (Aim 1). The study will collect feasibility data from baseline to three months (e.g., percentage who show up to the sessions, attrition).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control
Subjects will review standard health information on the health consequences of smoking.
Subjects will have blood drawn but it will not be tested for DNA damage.
standard health information
Subjects will review standard health information
Biomarker feedback
Subjects will review this standardized health information, plus receive information on DNA damage along with feedback of their DNA damage.
Subjects will have blood drawn and the feedback will be presented at Visit 2.
standard health information plus info. on DNA damage
Subjects will review standard health information and information on DNA damage
Biomarker feedback plus
Subjects will review this standardized health information, information on DNA damage along with feedback of their DNA damage, and will also will see images of their own cells with and without DNA damage.
Subjects will have blood drawn and the feedback and images will be presented at Visit 2.
Subjects will review standard health information and information on DNA damage, plus pictures of their DNA damage
Subjects will review standard health information and information on DNA damage, as well as review pictures of their cells' DNA damage
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
standard health information
Subjects will review standard health information
standard health information plus info. on DNA damage
Subjects will review standard health information and information on DNA damage
Subjects will review standard health information and information on DNA damage, plus pictures of their DNA damage
Subjects will review standard health information and information on DNA damage, as well as review pictures of their cells' DNA damage
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* smoke \> 5 cig/day during the last week
* be open to biomarker feedback
* not actively trying to quit
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Duke Cancer Institute
OTHER
Duke University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Isaac Lipkus, PhD
Role: PRINCIPAL_INVESTIGATOR
Duke University School of Nursing
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Duke University Medical Center
Durham, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Pro00075612
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.